IDEXX Laboratories
IDXX (NASDAQ)
IDEXX Laboratories (IDXX) stands out not only for its impressive commitment to social responsibility—enhancing veterinary access and promoting diversity—but also for its solid financial performance, achieving a 32.21% return over the past year. With a consensus rating of Buy from analysts, IDXX is seen as a compelling long-term investment, bolstered by recent upward revisions in earnings estimates for fiscal 2026. Investors can consider the stock's potential as it maintains a strong position in the market, highlighted by a median 12-month price target of $792.50.
Pros:
- Strong growth in diagnostics market
- High historical returns over 10 years
Cons:
- Recent negative returns over 3 and 6 months
- High beta of 1.72 indicating volatility
IDEXX Laboratories (IDXX) may be suitable for investors seeking long-term growth potential in the healthcare sector, particularly those who value companies with a strong commitment to social responsibility and innovation. However, the lack of a dividend and the stock's recent volatility may deter more risk-averse investors or those seeking immediate income.